Kornimate/medical-research-clean huggingface dataset:
superficial serratus plane block for modified radical mastectomy and axillary lymph node disection

Conditions: Postoperative Analgesia; Pain, Postoperative; Opioid Consumption

Summary: breast cancer is the most common type of cancer in women. mastectomy and axillary lymph node disection are commonly performed as part of the cancer management. this surgery can cause significant postoperative pain. the serratus plane block (spb) has been described for analgesia of the hemithorax and reported for many cases such as thoracoscopy, shoulder arthroscopy, breast surgery and axillary lymph node dissections. serratus plane block may be a viable alternative to current regional anaesthetic techniques such as thoracic paravertebral and central neuraxial blockade. the aim of this study is to determine effectiveness of ultrasound guided superficial serratus plane block in patients undergoing modified radical mastectomy and axillary lymph node dissection surgery.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologist's physiologic state i-iii patients undergoing modified radical mastectomy and axillary lymph node disection exclusion criteria: * chronic pain, bleeding disorders, renal or hepatic insufficiency,patients on chronic non-steroidal anti-inflammatory medications

Keywords: superficial serratus plane block modified radical mastectomy axillary lymph node disection bupivacaine
effect of vaginal ph on treatment effectiveness with misoprostol for first trimester missed abortions

Conditions: MISED ABORTION- Vaginal PH

Summary: vaginal ph has an effect on the effectiveness of treatment with misoprostol given vaginally for missed abortions in the first trimester


Eligibility criteria:
inclusion * missed abortion under 8 weeks by sac diameter over 18 years old informed concent given exclusion criteria: * missed abortion over 8 weeks hypersensitivity for pg vaginal bleeding suspected eup iud heart disease, htn, cerebral vascular disease, epilepsy intrauterine infection clooting disorder under 18
comparing calories at fast food restaurants

Conditions: Obesity

Summary: rating systems are intended to guide consumer choices. this project will determine if a previously developed scale that evaluates the "healthiness" of a restaurant is correlated with the actual choices consumers make when they patronize the restaurants. the study will also assess whether a restaurant marketed as "healthy" (subway) rates higher on this scale than another restaurant that makes no such claims (mcdonald's). finally, the investigators will compare the calorie purchases from these two restaurants among youths and their families who eat at each of the restaurants.


Eligibility criteria:
inclusion criteria: * 12-21 year olds that live in local area * like to eat at subway and mcdonald's
prophylactic administration of alpha blockers for prevention of urinary retention in males undergoing inguinal hernia repair under spinal anaesthesia.

Conditions: Inguinal Hernia; Urinary Retention

Summary: open inguinal hernia repair is one of the most common surgical procedures. despite the fact that different of anesthetic procedures are proposed as alternatives to spinal anesthesia, the combination of spinal anesthesia with open inguinal hernia repair is preferred from both surgeons and patients. one disadvantage of this combination is the high incidence of post-surgery urinary retention, especially in men above 50 years old. this complication is partially attribute to overstimulation of the a1 adrenergic receivers of the bladder and the prostate. preoperative administration of elective a1 blockers could inhibit this effect without side effects, since this drugs don't have systemic effect.


Eligibility criteria:
inclusion criteria: * unilateral inguinal hernia exclusion criteria: * asa score \>3 * hypotension * prostatic hypertrophy * complicated inguinal hernia * neurological diseases * inguinal hernia repair under general or local anaesthesia

Keywords: open inguinal hernia repair spinal anaesthesia urinary retention elective alpha blockers
small bowel endoscopic evaluation in familial adenomatous polyposis (fap)

Conditions: Familial Adenomatous Polyposis

Summary: background and study aim the relative risks of duodenal adenocarcinoma and ampullary carcinoma in familial adenomatous polyposis (fap) have been estimated 100 to 330 times higher than in general population. however risk factors, including a genotype-phenotype association for duodenal cancer in fap has not been fully understood. the aim of this study is to determine risk factors associated with the development of advanced duodenal polyposis and ampullary adenomas in colectomized patients with fap.


Eligibility criteria:
inclusion criteria: * patients with familial adenomatous polyposis with colectomy, or scheduled for surgery. exclusion criteria: * pregnancy, lactation

Keywords: familial adenomatous polyposis
a phase 2 study of interferon beta-1a (avonex®) in ulcerative colitis

Conditions: Active Ulcerative Colitis

Summary: the primary objective of the study is to evaluate the clinical activity of interferon beta-1a in participants with moderate to severe ulcerative colitis (uc). secondary objectives of this study are to determine (i) the safety and tolerability of interferon beta-1a in participants with moderate to severe uc, and (ii) the percentage of participants, with a decrease in the simple clinical colitis activity index (sccai) score of ≥3 points at week 8.


Eligibility criteria:
key inclusion criteria: * established diagnosis of ulcerative colitis (uc) for ≥6 months * 20 cm active disease at screening endoscopy * must have active uc with a mayo score/disease activity index (dai) of 6 to 13 points and moderate to severe disease on endoscopy (mayo endoscopic score of at least 2) despite prior or concomitant treatment * colonoscopy within past 5 years for extent of disease and to exclude polyps * for subjects with uc for more than 10 years, colonoscopy with appropriate biopsies within 1 year prior to screening to exclude dysplasia and neoplasia. * must be willing and able to practice effective birth control during the study and for 1 month after the last dose of study treatment. key exclusion criteria: * diagnosis of indeterminate colitis or crohn's disease * need for imminent surgery * diagnosis of primary sclerosing cholangitis or toxic megacolon * hemoglobin ≤9 g/dl * white blood cell count \< 3500 cells/mm\^3 * lymphocyte count \<1000 cells/µl * platelet count \<100,000 cells/µl * female subjects who are pregnant or who wish to become pregnant during the study, or who are lactating * known symptomatic colonic stricture * stool cultures positive for enteric infection * history of malignant disease * history of major abdominal surgery (e.g., gastrectomy) within past 5 years * history of small bowel or colonic obstruction or resection * history of drug or alcohol abuse (as defined by the investigator) within 2 years prior to screening * use of anti-diarrheal agents during the screening period * previous participation in this study * previous treatment with interferon beta or other interferon products note: other protocol defined inclusion/exclusion criteria may apply.
calcaneocuboid arthrodesis in triple arthrodesis by plate versus screw: randomized controlled trial

Conditions: Calcaneocuboid Osteoarthritis Secondary to Trauma

Summary: investigators aim to compare clinical and radiological outcome of use of plate versus screw fixation for calcaneocuboid arthrodesis in adult population.

the calcaneocuboid joint is stable, even although multiple conditions might affect the joint, ranging from osteoarthritis to fracture, subluxation, and dislocation. calcaneocuboid arthrodesis is more commonly performed as an adjunct procedure with other rearfoot procedures such as triple arthrodesis and is less used as isolated fusion.\[1\],\[2\],\[3\] what the most effective and least cost method for calcaneocuboid arthrodesis?! many conditions that may affect foot that cause pain ; and there are many methods for relieve that pain , one of these is arthrodesis , and calcaneocuboid joint one of the most affected joints , and commonly we do calcaneocuboid arthrodesis as a part of triple arthrodesis ( subtalar , talonavicular , calcaneocuboid ); the traditional fixation for a calcaneocuboid (cc) arthrodesis in triple arthrodesis is with a 6.5-mm cancellous screw. this procedure can be technically challenging. fixation with a locking compression plate (lcp) may be easier to perform while achieving compression perpendicular to the fusion site. investigators suppose that plate is more powerful than screw in calcaneocuboid arthrodesis. the purpose of this study was to compare the load to failure and the stiffness for each fixation method. \[4\],\[5\],\[6\] literature reveal that: more stability to the fusion site can be applied by using plate fixation. rationale of the research that: calcaneocuboid arthrodesis with screw is effective and least cost compare to plate fixation? \[7\]

Eligibility criteria:
inclusion criteria: all patients who will be operated by calcaneocuboid fusion for any indication age range 18-65 no paralytic patients exclusion criteria: * age \ 65 acute calcaneal fracture infection non union bone defect that need bone graft refusing to participate in the study neuropathic patients
a research study for latina women with breast cancer

Conditions: Cancer, Breast; Cancer-related Problem/Condition; Quality of Life; Hormone Dependent Neoplasms; Adherence, Medication

Summary: the purpose of this study is to examine the feasibility and preliminary efficacy of a psychosocial ehealth intervention designed to improve hormone therapy adherence among hispanic/latinx women with breast cancer. our proposed secondary outcomes are health-related quality of life and self-efficacy in managing hormone therapy side effects. the intervention components include breast cancer knowledge, hormone/endocrine therapy knowledge, stress awareness and management, social support, and enhanced communication and intimacy skills. the intervention will be delivered via a smartphone application over a 12-week period. all participants will receive the intervention application (described below). aside from using the smartphone application for the recommended 12 weeks, participation in this study includes three assessments: baseline (at the beginning of the research study), 6-week follow-up, and 12-week follow-up.


Eligibility criteria:
inclusion criteria: * female * diagnosis of breast cancer, non-metastatic, stage 0-iii (a, b, or c) * receiving or received endocrine/hormone therapy within the last 3 years (36 months) * at least 18 years of age * able to speak and read english or spanish * able to provide informed consent * self-identify hispanic/latina ethnicity exclusion criteria: * stage iv or metastatic * visual, hearing, voice, or motor impairment that would prevent completion of study procedures * diagnosis of an unmanaged psychotic disorder, bipolar disorder, dissociative disorder, or other diagnoses for which participation in this trial is either inappropriate or dangerous - this includes patients who have a life-threatening illness (e.g., end-stage kidney disease) or diagnosis of a chronic disease that is associated with a major functional impairment (e.g., fibromyalgia) * illicit substance or alcohol dependence * suicidal ideation, plan, intent * alzheimer's, dementia, or history of stroke * scheduled reconstruction surgery within 1 month of any study procedures or involvement.
efficacy of an electronic system to support clinical decisions in adults with type 2 diabetes mellitus.

Conditions: Diabetes Mellitus, Type 2

Summary: to assess the efficacy of an electronic system to support clinical decisions based on an evidence-based clinical practice guide for metabolic control of adults with type 2 diabetes mellitus through clinical and cluster-randomized controlled trial in a colombian population.


Eligibility criteria:
inclusion criteria: * no prior exposure to the tool (through development and beta testing) * access to an organized diabetes pathway consistent with the sanitas eps (entidad promotora de salud) diabetes mellitus 2 guideline. exclusion criteria: * terminally ill

Keywords: diabetes mellitus, type 2 hemoglobin a, glycosylated
amyloid prediction in early stage alzheimer's disease from acoustic and linguistic patterns of speech - past extension

Conditions: Alzheimer Disease; Preclinical Alzheimer's Disease; Prodromal Alzheimer's Disease; Alzheimer's Disease (Incl Subtypes); Mild Cognitive Impairment

Summary: the primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage alzheimer's disease, based on archival spoken or written language samples, as measured by the auc of the receiver operating characteristic curve of the binary classifier distinguishing between amyloid positive and amyloid negative arms. secondary objectives include (1) evaluating how many years before diagnosis of mci such algorithms work, as measured on binary classifier performance of the classifiers trained to classify mci vs cognitively normal (cn) arms using archival material from the following time bins before mci diagnosis: 0-5 years, 5-10 years, 10-15 years, 15-20 years, 20-25 years; (2) evaluating at what age such algorithms can detect later amyloid positivity, as measured on binary classifier performance of the classifiers trained to classify amyloid positive vs amyloid negative arms using archival material from the following age bins: younger than 50, 50-55, 55-60, 65-70, 70-75 years old.


Eligibility criteria:
inclusion criteria: * subjects are fully eligible for and have completed the amypred (amyloid prediction in early stage alzheimer's disease from acoustic and linguistic patterns of speech) study. (see https://clinicaltrials.gov/ct2/show/nct04828122) * subject has access to audio or written recordings created by them that are available for collection. * subject consents to take part in past extension study. exclusion criteria: * subject hasn't completed the full visit day in the amypred study.

Keywords: alzheimer's disease preclinical alzheimer's disease prodromal alzheimer's disease mild cognitive impairment normal cognition amyloid speech acoustic language linguistic machine learning artificial intelligence
sophisticated assessment of disease burden in patients with fabry disease

Conditions: Fabry Disease

Summary: to detect early signs of cardiac and metabolic alterations as well as to evaluate the progression of cardiac and metabolic impairments in mildly affected patients with fabry disease using high sensitive diagnostic methods.

observational study evaluating the use of cardiac mri with late enhancement technique, echocardiography, 24h holter ecg, plasma lyso-gb3 and urinary gb3, to identify early signs of progressive fabry disease.

Eligibility criteria:
inclusion criteria: 1. women: a confirmed exonic mutation within the α-galactosidase gene men: a confirmed exonic mutation within the α-galactosidas gene and/or reduced α- galactosidase activity 2. female patients ≥ 25 years-old and male patients ≥ 25 years-old 3. the patient has not received enzyme replacement therapy for treatment of fabry disease 4. the patient must have voluntarily signed an institutional review board (irb)/independent ethics committee (iec)-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient 5. the patient has already mild symptoms of fabry disease presented in at least one minor organ involvement, e.g. proteinuria 1, mild cardiac symptoms not needing treatment yet, pain attacks, gastrointestinal symptoms or history of tia. exclusion criteria: 1. the patient has received ert or investigational product(s) for any reason within 30 days prior to study entry. 2. any contraindication for mri-diagnosis 3. incompatibility to mri contrast agent (elevated serum creatinine - according to spc of contrast medium) the patient is unable to comply with the protocol, e.g., has a clinically relevant medical condition making implementation of the protocol difficult; has an uncooperative attitude; is unable to return for study evaluations; or is otherwise unlikely to complete the study, as determined by the investigator. 4. planned ert within the next 24 months (nevertheless if a ert becomes medically necessary in the observational period ert might be introduced)

Keywords: fabry
longitudinal assessment of pain-related patient-reported outcomes after surgery

Conditions: Pain, Postoperative; Adult; Pain Measurement; Functional Status; Pain Management; Neuralgia; Analgesia

Summary: little is known about pain-related outcomes experienced by patients in the first few weeks after surgery, once they are discharged from hospital. this study aims to characterize pain, pain-related interference, and early neuropathic pain in the sub-acute phase after surgery.

a high proportion of patients experience moderate to severe pain after surgery. however, most of the knowledge about this comes from studies where patients are evaluated in the hours and up until the first postoperative day. alternatively, patients are assessed several months (eg 3 or later) after surgery, to evaluate the development of chronic pain related to surgery (cpsp) and most patients do not develop cpsp. this study aims to learn how patients recover concerning pain and function once they return home after surgery. how long is it before they can resume their daily activities and to do so in comfort? do they take treatment for pain? do they have pain restricted to the surgical incision or it is more widespread? there is little knowledge as to whether there are signs of nerve injury in the days close to surgery. this type of pain might lead to chronic pain in later stages. patients will be assessed at three time points: the first day after surgery, the 7th day after surgery, and 1 month. the information we obtain will offer healthcare providers, from multiple hospitals, information about the care they provide to their patients for pain while patients are still in hospital and insights as to how the care might be improved, once they are discharged.

Eligibility criteria:
inclusion criteria: 1. adult 2. on the first post-operative day and back on the ward for at least 6 hours 3. gives consent for assessment at 3-time points exclusion criteria: 1. the patient is unable to communicate 2. the patient is cognitively impaired 3. the patient is asleep 4. the patient is too ill or in too much pain and does not wish to be interviewed 5. the patient does not wish to fill in the outcomes questionnaire
epinephrine in irrigation fluid for visualization during ankle surgery

Conditions: Intraoperative Bleeding

Summary: the purpose of this study is to evaluate the effect of epinephrine in irrigation fluid for visual clarity in ankle arthroscopic surgery.

the primary outcomes are: * visual clarity during ankle arthroscopic surgery, which will be evaluated by visual analog scale from 0-10, * and the intraoperative surgeon's discomfort related to bleeding, that will be measured by visual numeric rating scale from 0-3.

Eligibility criteria:
inclusion criteria: * males and females ages over 18 years * patients who undergo ankle arthroscopic surgery * patients who are able to read and give informed consent on their own behalf exclusion criteria: * patients with any known cardiac diseases * uncontrolled hypertension (\> 180/110 mmhg) * revision case * younger than 18 years of age * pregnant women
thailand attr-cm registry

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Summary: the investigators of this registry aim to study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with attr amyloidosis in thailand longitudinally. this will enable the investigators to study this disease in depth. with a better understanding, the investigators can aim to develop early screening programs for at-risk patients, raising awareness among non-cardiologists. as amyloid-specific therapies have now become available in thailand, the findings of this registry can be helpful for epidemiological studies in thailand.


Eligibility criteria:
inclusion criteria: * age \> 18 years. * all patients diagnosed with attr-cm (transthyretin cardiomyopathy) who have either symptomatic or asymptomatic must have evidence of cardiac involvement by echocardiogram as defined by left ventricle wall thickness of ≥ 12 mm and with at least one of the following criteria: * positive scintigraphy by 99mtc-dpd \[99mtc-3,3-diphosphono-1,2-propano-dicarboxylic acid\] or 99mtc-pyp \[pyrophosphate\] or 99mtc-hmdp \[hydroxymethylene diphosphate\] with perugini grade ≥ 2 and/or h/cl (heart to contralateral lung) ratio \> 1.5 * positive scintigraphy by 99mtc-dpd \[99mtc-3,3-diphosphono-1,2-propano-dicarboxylic acid\] or 99mtc-pyp \[pyrophosphate\] or 99mtc-hmdp \[hydroxymethylene diphosphate\] with perugini grade 1 and positive cardiac biopsy tissue confirmed which congo red stain ≥ 4 sites * positive scintigraphy by 99mtc-dpd \[99mtc-3,3-diphosphono-1,2-propano-dicarboxylic acid\] or 99mtc-pyp \[pyrophosphate\] or 99mtc-hmdp \[hydroxymethylene diphosphate\] with perugini grade 1 with positive non-cardiac biopsy tissue confirmed by congo red stain * abnormalities on cmr (cardiac mri) \[subendocardium lge (late gadolinium enhancement) and/or elevated native t1 value and/or increased extracellular volume (ecv \> 0.4)\] with positive non-cardiac and/or cardiac tissue biopsy confirmed by congo red stain exclusion criteria: * diagnosed with amyloidosis caused by proteins other than transthyretin (light chain amyloidosis, etc.) * diagnosed with secondary amyloidosis

Keywords: transthyretin amyloid cardiomyopathy (attr-cm) heart failure cardiomyopathy
patient-derived xenograft (pdx) modeling in adult patients with metastatic or recurrent sarcoma

Conditions: Sarcoma

Summary: patients with recurrent or metastatic sarcoma will be consented to develop a patient derived xenograft (pdx or tumorgraft) model of their tumor to perform drug sensitivity testing. the purpose of the study is to evaluate the accuracy of the patient derived xenograft (pdx) model in predicting patient clinical response to the same drug treatment.


Eligibility criteria:
* 15 years of age or older * patients with metastatic sarcoma who have had no more than one prior systemic treatment for metastatic disease * patients with recurrent sarcoma at relapse * patients with confirmed histological diagnosis of sarcoma or suspected diagnosis of sarcoma. some specific subtypes of sarcoma are not eligible (gastrointestinal stromal tumor (gist), carcinosarcoma, sarcomatoid mesothelioma, and metastatic phyllodes tumor) * if initial suspected diagnosis of sarcoma, must have sarcoma diagnosis confirmed prior to proceeding with pdx drug sensitivity testing * must have measureable disease for computed tomography (ct) scan or magnetic resonance imaging (mri) evaluation following biopsy or surgery to obtain tissue for pdx development. * no plan for concurrent chemoradiation, for target lesions that will be used for drug treatment correlation with pdx * fresh tumor tissue available for pdx development * eastern cooperative oncology group performance status of 0-1 * life expectancy exceeds 6 months * plan to receive systemic therapy * informed consent

Keywords: pdx tumorgraft patient derived xenograft sarcoma